{
    "clinical_study": {
        "@rank": "147940", 
        "acronym": "TST", 
        "arm_group": {
            "arm_group_label": "Tysabri", 
            "description": "All subjects took Tysabri and also had an MRI which we use for the baseline evaluation. Over 5 years, some patients remained on Tysabri, some started another drug and others were off Tysabri for a time but then restarted."
        }, 
        "brief_summary": {
            "textblock": "The primary aim of this study is to evaluate the effect of using Tysabri on changes in the\n      brain using MRI and on disease progression in patients with relapsing-remitting Multiple\n      Sclerosis over 5 years."
        }, 
        "brief_title": "A Longitudinal Study of Brain Atrophy in MS Patients Over 5 Years", 
        "completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "condition": "Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis", 
                "Atrophy"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a prospective, observational, single-blinded, longitudinal study of natalizumab\n      effect on brain atrophy development and disability progression in multiple sclerosis\n      patients over 5 years, which will evaluate originally treated patients with natalizumab who\n      participated in a prospective 1- and 2-year VWMTR study. (Zivadinov et al., 2011b) All\n      subjects will be assessed at 5-year follow-up with the same clinical examinations and will\n      obtain 1.5T MRI examination on the same scanner that did not undergo any upgrade changes in\n      the period of 5 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participation in natalizumab 1-year follow-up study\n\n          -  Participants were aged 18-65\n\n          -  Have clinically definite MS according to the Polman criteria of either RR or RSP\n             disease type\n\n          -  EDSS scores \u22646.5\n\n          -  disease duration <30 years\n\n          -  normal kidney function (creatinine clearance >59 mL/min)\n\n          -  started therapy either with natalizumab or IM interferon beta-1a (IFN\u03b2-1a)\n\n          -  Signed informed consent\n\n          -  Normal kidney functioning (creatinine clearance >59)\n\n          -  None of the exclusion criteria\n\n        Exclusion Criteria:\n\n          -  A clinically significant infectious illness (e.g., cellulitis, abscess, pneumonia,\n             septicemia) within 30 days prior to 5-year follow-up visit\n\n          -  Nursing mothers or pregnant women who will need to undergo 5-year follow-up MRI\n\n          -  Unwillingness or inability to comply with the requirements of this protocol including\n             the presence of any condition (physical, mental, or social) that is likely to affect\n             the subject's ability to comply with the study protocol\n\n          -  Any other reasons that, in the opinion of the Investigator, indicate that the subject\n             is unsuitable for enrollment into this study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Multiple Sclerosis - relapsing remitting"
            }
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 1, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01847287", 
            "org_study_id": "TST5"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Multiple sclerosis", 
            "Tysabri", 
            "MRI", 
            "Natalizumab"
        ], 
        "lastchanged_date": "May 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Buffalo", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "14203"
                }, 
                "name": "Buffalo Neuroimaging Analysis Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Prospective, Observational, Single-blinded, Longitudinal Study of Natalizumab Effect on Brain Atrophy and Disability in Multiple Sclerosis Patients Over 5 Years.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "USA: SUNY University at Buffalo Health Sciences Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Evaluation of MRI images from baseline in comparison with a 5 year MRI.", 
            "measure": "The primary aim of this study is to define the effect of the number of natalizumab cycles on development of brain atrophy and progression of disability in originally treated patients with natalizumab in relapsing multiple sclerosis (MS).", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01847287"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University at Buffalo", 
            "investigator_full_name": "Robert Zivadinov, MD, PhD", 
            "investigator_title": "Director, Buffalo Neuroimaging Analysis Center, Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "To evaluate any effect of the number of Tysabri cycles on lesion volume.", 
            "measure": "The secondary objective of this study is to define the effect of the number of natalizumab cycles on accumulation of T2-LV and T1-LV and their VW-MTR changes over 5 years.", 
            "safety_issue": "No", 
            "time_frame": "5 years"
        }, 
        "source": "University at Buffalo", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University at Buffalo", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2013"
    }
}